Sweating Reduced: What Could Be Causing It

How Normal Sweating Works and Why It Can Fail

Your body produces sweat through 2 to 4 million eccrine glands distributed across nearly every skin surface. These glands are innervated by postganglionic sympathetic cholinergic fibers that release acetylcholine in response to rising core temperature, emotional stress, or gustatory stimuli 1. When any link in this thermoregulatory chain breaks, sweating drops below the volume needed to cool the body effectively.

The Thermoregulatory Chain

The sequence begins in the hypothalamic preoptic area, which detects blood temperature changes as small as 0.1 °C. Signals travel down the intermediolateral cell column of the spinal cord, synapse in sympathetic ganglia, and reach the eccrine gland via unmyelinated C fibers. A lesion or dysfunction at any point along this pathway reduces or eliminates sweat output on the affected dermatome 2.

Why This Matters Clinically

Sweat evaporation dissipates up to 600 kcal per hour during heavy exercise. Without adequate perspiration, core temperature can rise to dangerous levels within 10 to 15 minutes of vigorous activity in hot environments. The 2022 CDC heat-related mortality data reported 1,714 heat-related deaths in the United States, with impaired thermoregulation identified as a contributing factor in a large subset of cases involving older adults and those on anticholinergic medications 3.

Neurological Causes of Reduced Sweating

Damage to the autonomic nervous system is the single most common explanation for generalized or segmental hypohidrosis. The pattern of sweat loss often helps localize the lesion.

Diabetic Autonomic Neuropathy

Type 2 diabetes is the leading cause of autonomic neuropathy worldwide. A prospective cohort study of 639 patients with type 2 diabetes found that 34% had sudomotor dysfunction on quantitative sudomotor axon reflex testing (QSART), even before developing symptoms of peripheral neuropathy 4. Sweat loss in diabetic neuropathy typically begins distally (feet and lower legs) and progresses proximally, following a length-dependent pattern. Patients often notice their feet stay dry while their trunk or face compensates with excess sweating.

Pure Autonomic Failure and Multiple System Atrophy

Pure autonomic failure (PAF) and multiple system atrophy (MSA) both cause widespread anhidrosis as a cardinal feature. In MSA, thermoregulatory sweat testing reveals diffuse anhidrosis in over 80% of patients at diagnosis 5. The American Academy of Neurology's 2019 practice guideline on autonomic testing recommends TST and QSART as first-line assessments when generalized anhidrosis accompanies orthostatic hypotension or parkinsonian features 6.

Other Neurological Causes

Small fiber neuropathy from any etiology (amyloidosis, Sjögren syndrome, sarcoidosis, celiac disease) can reduce sweating in a patchy or regional distribution. Horner syndrome causes anhidrosis confined to the ipsilateral face and upper trunk. Spinal cord injuries produce anhidrosis below the level of the lesion.

Medication-Induced Hypohidrosis

Dozens of prescription and over-the-counter drugs reduce sweating as a side effect. The mechanism almost always involves anticholinergic blockade of muscarinic receptors on eccrine glands or central suppression of thermoregulatory signaling.

High-Risk Drug Classes

Anticholinergic burden scores help quantify risk. A 2020 systematic review in the Journal of the American Geriatrics Society found that patients with a cumulative anticholinergic burden score of 3 or higher had a 2.7-fold increased risk of heat-related emergency department visits compared to age-matched controls 7.

Common offenders include:

• Oxybutynin and other bladder antimuscarinics. Oxybutynin reduces sweat volume by up to 60% in dose-response studies 8.
• First-generation antihistamines (diphenhydramine, chlorpheniramine) with strong anticholinergic properties.
• Tricyclic antidepressants (amitriptyline, nortriptyline).
• Typical and atypical antipsychotics, particularly clozapine and olanzapine.
• Topiramate, which causes oligohidrosis in 5 to 10% of adult users and up to 25% of pediatric users, per FDA labeling 9.
• Botulinum toxin injections to the axillae or palms, which eliminate focal sweating by design.

What to Do If You Suspect a Drug Cause

Do not stop medications without consulting your prescriber. A stepwise approach involves reviewing the anticholinergic burden, identifying the drug most likely responsible, and trialing dose reduction or substitution. Mirabegron, for example, is a beta-3 agonist alternative to oxybutynin that does not block muscarinic receptors and preserves sweat function.

Skin and Gland Disorders That Impair Sweating

When eccrine glands themselves are damaged, destroyed, or occluded, sweating decreases regardless of intact neural pathways.

Burns, Radiation, and Scarring

Full-thickness burns destroy eccrine glands permanently. A study of 112 burn survivors found that grafted skin showed no functional sweat glands on iodine-starch testing in 97% of cases, even 5 years after the burn 10. Radiation dermatitis produces a similar effect, with fibrosis replacing glandular tissue over months to years.

Dermatological Conditions

Psoriasis and lichen sclerosus can occlude sweat pores in affected areas. Miliaria (heat rash) represents a temporary obstruction of eccrine ducts by keratin plugs. Scleroderma causes fibrotic replacement of skin appendages, including eccrine glands, in a distribution that mirrors the extent of skin thickening.

Eccrine Gland Atrophy With Aging

Sweat gland density and output decline with age. Histological data from cadaveric skin specimens show that the number of active eccrine glands per square centimeter drops by approximately 15% per decade after age 40 11. This age-related decline compounds the risk of heat illness in older adults who also take anticholinergic medications.

Inherited and Metabolic Causes

Several genetic conditions affect sweat gland development or autonomic nerve function from birth.

Fabry Disease

Fabry disease, an X-linked lysosomal storage disorder, causes progressive accumulation of globotrianosylceramide (Gb3) in small nerve fibers and sweat glands. Reduced sweating is often the earliest clinical feature, appearing in childhood years before renal or cardiac involvement. A survey of 366 male Fabry patients found that 53% reported hypohidrosis as their first symptom, at a mean age of onset of 9.4 years 12. The European Fabry Working Group has stated: "Hypohidrosis in boys with acroparesthesias should prompt genetic testing for Fabry disease, as enzyme replacement therapy can modify disease trajectory when initiated early" 12.

Ectodermal Dysplasia

Hypohidrotic ectodermal dysplasia (HED), caused by mutations in the EDA, EDAR, or EDARADD genes, results in absent or markedly reduced eccrine glands. Affected individuals are born with the condition and remain at lifelong risk of hyperthermia. Carrier females may show a mosaic pattern with alternating lines of normal and reduced sweating along Blaschko lines.

Ross Syndrome

Ross syndrome is an acquired condition characterized by segmental anhidrosis, tonic pupils (Adie pupils), and areflexia. It is thought to represent a degenerative autonomic ganglionopathy. Progression is slow but can eventually involve large body surface areas.

Diagnosing Reduced Sweating

Diagnosing the cause of hypohidrosis requires matching the distribution pattern with the clinical context. A systematic evaluation starts with history (medications, comorbidities, family history) and ends with targeted autonomic testing.

Thermoregulatory Sweat Test (TST)

TST is the gold standard for mapping whole-body sweat distribution. The patient is dusted with an indicator powder (alizarin red or iodinated corn starch), then placed in a controlled heat chamber (ambient temperature 45 to 50 °C, humidity 35 to 40%) for 45 to 60 minutes. Areas that fail to change color indicate anhidrosis. TST can distinguish central from peripheral lesions based on the distribution pattern and is available at specialized autonomic laboratories. Dr. Wolfgang Singer, a neurologist at the Mayo Clinic Autonomic Disorders Center, has noted: "The thermoregulatory sweat test remains our most sensitive tool for detecting and quantifying global sweat loss, and the pattern it reveals often narrows the differential diagnosis before any other test is performed" 5.

Quantitative Sudomotor Axon Reflex Test (QSART)

QSART uses iontophoresis of acetylcholine to stimulate postganglionic sudomotor fibers at four standardized sites (forearm, proximal leg, distal leg, foot). Sweat volume is measured in microliters per square centimeter per minute. Values below the 5th percentile for age and sex indicate postganglionic sudomotor failure 6.

Additional Testing

Skin biopsy with measurement of intraepidermal nerve fiber density (IENFD) can confirm small fiber neuropathy. Blood tests for HbA1c, alpha-galactosidase A activity (Fabry disease), anti-SSA/SSB antibodies (Sjögren syndrome), and serum protein electrophoresis (amyloidosis) help identify systemic causes.

Treatment and Management

Treatment depends entirely on the underlying cause. There is no FDA-approved drug that directly stimulates eccrine gland secretion.

Treating the Root Cause

For diabetic neuropathy, optimizing glycemic control (target HbA1c <7.0% per ADA guidelines) can slow further sudomotor nerve damage, though reversal of established loss is unlikely 13. Enzyme replacement therapy with agalsidase beta (1 mg/kg IV every 2 weeks) in Fabry disease has shown modest improvement in sweat function when initiated before irreversible gland damage occurs 12. Medication substitution or dose reduction resolves drug-induced hypohidrosis in most cases within 1 to 4 weeks of discontinuation.

Heat Safety Precautions

Patients with significant hypohidrosis need a heat safety plan. Practical measures include:

• Avoiding outdoor activity when the heat index exceeds 32 °C (90 °F).
• Wearing lightweight, moisture-wicking clothing.
• Pre-cooling with cold water immersion or ice towels before exercise.
• Carrying a spray bottle for external evaporative cooling.
• Monitoring core temperature with an ingestible sensor if exercising in warm environments.

When Sweating Will Not Return

In conditions where eccrine glands have been physically destroyed (full-thickness burns, advanced scleroderma, ectodermal dysplasia), sweating will not recover. These patients require lifelong behavioral adaptation to prevent heat illness. Air conditioning, activity modification, and caregiver education are the primary interventions.

Reduced Sweating and Hormone Therapy

Patients on testosterone replacement therapy (TRT) sometimes report changes in sweat patterns. Testosterone increases metabolic rate, which can shift thermoregulatory thresholds and alter sweat onset timing. Women undergoing menopause or receiving estradiol therapy may experience fluctuations in sweat volume related to declining estrogen levels, which modulate hypothalamic thermoregulatory set points 14.

GLP-1 Agonists and Sweating

GLP-1 receptor agonists (semaglutide, tirzepatide) have not been associated with hypohidrosis in clinical trials. In the STEP-1 trial (N=1,961), sweating was not reported as a treatment-emergent adverse event at a higher rate in the semaglutide group than placebo 15. Patients who lose significant weight on GLP-1 therapy may subjectively notice less sweating during activity, but this reflects reduced metabolic heat production from lower body mass rather than glandular dysfunction.